Prior Authorization Request Nevada Medicaid – OptumRx

Remicade® (infliximab)

Submit fax request to: 855-455-3303

Purpose: For a prescribing physician to request prior authorization for Remicade® (infliximab).*

Questions: If you have questions, call the OptumRx Call Center for Nevada Medicaid at 855-455-3311.

DATE OF REQUEST:						
RECIPIENT INFORMATION						
Last Name, First Name, Middle Initial:				Date of Birth:		
Recipient ID:	Gender:	☐ Male ☐ Female	Phone:			
PRESCRIBING PROVIDER INFORMATION						
Name:	NPI:		Specialty:			
Phone:	Fax (required):					
Person to contact regarding this request:						
DIAGNOSIS AND REQUESTED DRUG						
Name: Remicade		Strength:				
Dosage:		Duration:				
Please document the recipient's diagnosis:						
☐ Ankylosing Spondylitis						
\square The recipient has had an inadequate res	ponse to	NSAIDS or contraindica	ation to treat	ment with an NSAID.		
☐ Psoriatic Arthritis						
\Box The recipient has had an inadequate response to NSAIDS or contraindication to treatment with an NSAID.						
☐ Plaque Psoriasis						
☐ The recipient has failed to adequately respond to a topical agent.						
☐ Ulcerative Colitis						
☐ The recipient has a diagnosis of moderate to severe ulcerative colitis.						
Recipient has failed to adequately response	ond to 1 o	r more of the following:	standard the	rapies: corticosteroids, 5-		
aminosalicylic acid agents, immunosup	oresants a	and/or Thiopurines.				
☐ Crohn's Disease						
☐ Rheumatoid Arthritis						
U Other:	_					
CLINICAL INFORMATION						
Check the applicable boxes to indicate each ite	em as true	e for the recipient:				
\square The recipient has had a rheumatology cons						
The recipient has had a dermatology consult. Date: Duration of disease: (if applicable).						
The recipient has fistulizing Crohn's disease (Crohn's disease only).						
The recipient has mild disease activity.						
☐ The recipient has moderate disease activity.☐ The recipient has high/severe disease activity.						
☐ The recipient has high/severe disease activity. ☐ The recipient does not have moderate to severe heart failure (NYHA class III or IV).						
☐ The recipient does not have a history of treated lymphoproliferative disease in the previous 5 years.						
☐ The recipient does not have acute or chronic liver disease classified as Child-Pugh class B or C.						
☐ The recipient does not have multiple sclerosis or another demyelinating disorder.						
The recipient does not have an active infection or history of recurring infections.						
The recipient has had a negative tuberculin test prior to initiating requested treatment.						
 The recipient has had a positive tuberculin test prior to initiating requested treatment. Treatment with isoniazid was started ≥1 month prior to initiating requested treatment (only if test was positive). 						
☐ The recipient has an allergy, history of unacceptable/toxic side effects, drug-drug interaction or therapeutic failure with						
Cimzia®, Enbrel® and Humira® (if indicated for diagnosis). <i>Please document</i> :						
☐ Remicade® is being requested for a unique indication that is supported by peer-reviewed literature or a unique FDA-						
approved indication (document diagnosis at						

List the medications that were tried and failed for the given diagnosis:				
Drug Name	Reason for Failure	Date(s)		
Additional clinical information (if applicable):				
PROVIDER CERTIFICATION – Prescriber's signature and date required.				
I hereby certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by Nevada Medicaid.				
Prescriber's Signature:		Date:		

This authorization request is not a guarantee of payment. Payment is contingent upon eligibility, available benefits, contractual terms, limitations, exclusions, coordination of benefits and other terms and conditions set forth by the benefit program. The information on this form and on accompanying attachments is privileged and confidential and is only for the use of the individual or entities named on this form. If the reader of this form is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, the reader is hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If this communication is received in error, the reader shall notify sender immediately and destroy all information received.

^{*} Authorization will not be given for the use of more than one biologic at a time (combination therapy).